Physician profile
Samer S Eldeiry
NPI 1326045691
$8,958.24
in general payments reported to CMS, 2019-2025
37 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $200 · 2021: $1,008 · 2022: $1,529 · 2023: $1,960 · 2024: $1,888 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Travel and Lodging: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.09 |
| Travel and Lodging | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,196.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,117.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $790.61 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $708.08 | 2019-2024 | Omnipod |
| Amgen INC. | $638.67 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $443.58 | 2019-2025 | |
| Pfizer INC. | $417.22 | 2021-2025 | |
| Medtronic, INC. | $395.63 | 2022-2024 | Minimed 780g |
| Dexcom, INC. | $389.71 | 2021-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $350.08 | 2019-2023 | Tepezza |
| Mannkind Corporation | $291.28 | 2019-2025 | Afrezza |
| Ipsen Biopharmaceuticals, INC | $289.69 | 2019-2023 | Somatuline Depot |
| Abbvie INC. | $279.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $236.16 | 2019-2024 | Lokelma, Farxiga |
| Radius Health, INC. | $138.43 | 2019-2025 | Tymlos |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Eldeiry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.